Загрузка...
Evaluation of high-risk clinicopathological indicators in gastrointestinal stromal tumors for prognosis and imatinib treatment outcome
BACKGROUND: Although the clinical benefit of imatinib adjuvant therapy for high-risk patients with gastrointestinal stromal tumor (GIST) has been proven, the recurrence rate still remains high. This study aimed to sub-divide high-risk GIST patients with some “very high-risk” factors for more precise...
Сохранить в:
| Главные авторы: | , , , , , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
BioMed Central
2014
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4057930/ https://ncbi.nlm.nih.gov/pubmed/24906683 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-230X-14-105 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|